Investment Analysts’ Recent Ratings Changes for Zimmer Biomet (ZBH)

Zimmer Biomet (NYSE: ZBH) has recently received a number of price target changes and ratings updates:

  • 2/5/2018 – Zimmer Biomet had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock. They wrote, “ZBH received FDA clearance for its Persona cementless knee, earlier than we expected.””
  • 1/31/2018 – Zimmer Biomet had its price target raised by analysts at Leerink Swann from $142.00 to $146.00. They now have an “outperform” rating on the stock.
  • 1/31/2018 – Zimmer Biomet was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $168.00 price target on the stock, up previously from $120.00.
  • 1/31/2018 – Zimmer Biomet had its “buy” rating reaffirmed by analysts at Robert W. Baird.
  • 1/30/2018 – Zimmer Biomet had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $144.00 price target on the stock.
  • 1/30/2018 – Zimmer Biomet had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $140.00 price target on the stock.
  • 1/30/2018 – Zimmer Biomet had its price target raised by analysts at Needham & Company LLC from $144.00 to $155.00. They now have a “strong-buy” rating on the stock.
  • 1/29/2018 – Zimmer Biomet had its price target raised by analysts at SunTrust Banks, Inc. to $142.00. They now have a “buy” rating on the stock.
  • 1/29/2018 – Zimmer Biomet had its price target raised by analysts at Morgan Stanley from $140.00 to $150.00.
  • 1/11/2018 – Zimmer Biomet was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 1/5/2018 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $132.00 price target on the stock.
  • 1/5/2018 – Zimmer Biomet had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 12/19/2017 – Zimmer Biomet was upgraded by analysts at Goldman Sachs Group Inc from a “sell” rating to a “neutral” rating. They now have a $125.00 price target on the stock.
  • 12/19/2017 – Zimmer Biomet had its “hold” rating reaffirmed by analysts at Canaccord Genuity. They now have a $125.00 price target on the stock. They wrote, “We maintain our HOLD rating following the announcement that Zimmer has named Bryan Hanson, former EVP and President of Medtronic’s Minimally Invasive Therapies Group, as CEO effective immediately. The announcement ends the five-month search for a new leader after former CEO David Dvorak resigned early in the Q3/17. Additionally, interim CEO Dan Florin will remain with the company as CFO. We view the hire positively as it removes the near-term overhang of management uncertainty and adds a seasoned medtech veteran to the management team and board. Additionally, we expect the new CEO to be well received by investors given our recent diligence suggested Mr. Hanson was at the top of investors’ short list of potential candidates.””
  • 12/19/2017 – Zimmer Biomet had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 12/19/2017 – Zimmer Biomet was upgraded by analysts at Wells Fargo & Co from a “market perform” rating to an “outperform” rating.

Shares of Zimmer Biomet Holdings Inc (NYSE ZBH) traded up $0.13 on Monday, reaching $116.52. 1,467,080 shares of the company’s stock traded hands, compared to its average volume of 1,567,795. The company has a quick ratio of 0.83, a current ratio of 1.52 and a debt-to-equity ratio of 0.76. Zimmer Biomet Holdings Inc has a one year low of $108.03 and a one year high of $133.49. The firm has a market capitalization of $23,670.00, a price-to-earnings ratio of 12.92, a P/E/G ratio of 2.04 and a beta of 1.08.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the consensus estimate of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.03 billion. During the same period in the prior year, the business posted $2.14 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. sell-side analysts predict that Zimmer Biomet Holdings Inc will post 7.82 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Monday, January 29th. Shareholders of record on Friday, December 29th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.96 annualized dividend and a yield of 0.82%. Zimmer Biomet’s payout ratio is currently 10.64%.

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Receive News & Ratings for Zimmer Biomet Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply